Biogen Ma Company Profile
What is the competitive landscape for BIOGEN MA
BIOGEN MA has one approved drug.
There are three US patents protecting BIOGEN MA drugs.
Summary for Biogen Ma
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Biogen Ma: | See patent lawsuits for Biogen Ma |
| PTAB Cases with Biogen Ma as patent owner: | See PTAB cases with Biogen Ma as patent owner |
Drugs and US Patents for Biogen Ma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | 10,385,341 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | 10,669,546 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Biogen Ma | QALSODY | tofersen | SOLUTION;INTRATHECAL | 215887-001 | Apr 25, 2023 | RX | Yes | Yes | 10,968,453 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Biogen Ma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20220077933 | ⤷ Start Trial |
| Japan | 2024105714 | ⤷ Start Trial |
| Chile | 2016002509 | ⤷ Start Trial |
| Canada | 2942394 | ⤷ Start Trial |
| Cyprus | 1123288 | ⤷ Start Trial |
| Brazil | 112016021848 | ⤷ Start Trial |
| Cyprus | 1123288 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biogen Ma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3126499 | 34/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; REGISTRATION NO/DATE: EU/1/23/1783 (MITTEILUNG) 20240603 |
| 3126499 | LUC00359 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; AUTHORISATION NUMBER AND DATE: EU/1/23/1783 20240603 |
| 3126499 | 2490031-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; REG. NO/DATE: EU/1/23/1783 20240603 |
| 3126499 | 2024C/538 | Belgium | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; AUTHORISATION NUMBER AND DATE: EU/1/23/1783 20240603 |
| 3126499 | 24C1039 | France | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; REGISTRATION NO/DATE: EU/1/23/1783 20240603 |
| 3126499 | C20240035 | Finland | ⤷ Start Trial | |
| 3126499 | 301293 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TOFERSEN; REGISTRATION NO/DATE: EU/1/23/1783 20240603 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |

